Clinical Data Novo says oral semaglutide works in diabetic kids PharmaphorumNovo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.Clinical DataMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaphorum Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO changeNext: BBOT shakes up leadership as RAS competitors get more visibility Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
